Alterations in cell cycle control have been found in MDS-MSCs: higher expression of cyclin-dependent kinase inhibitor 2B (CDKN2B) could be responsible for the low proliferative capacity of MSCs, favoring clonal progression [166]. The gene discussed is CDKN2B; the disease is myelodysplastic syndrome.